Denosumab biosimilar(Enzene Biosciences)

地舒单抗生物类似药 (Enzene Biosciences)

Report date: 2026/02/24 20:00:16

Base Information

Drug NameDenosumab biosimilar(Enzene Biosciences)
Drug Alias NameOsqayENZ-215
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsBone ResorptionOsteoporosis, Postmenopausal
Global Approved IndicationsBone Resorption
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2026/01/08
Country/TerritoryCzechiaBulgariaPoland +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesEnzene Biosciences Ltd
China Registration ClassN/A

Develop Information

Active CompaniesEnzene Biosciences LtdTheramex Ireland LtdAlkem Laboratories Ltd
Inactive CompaniesN/A
Active IndicationsBone ResorptionOsteoporosis, Postmenopausal
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A